Walvax Biotechnology Co.,Ltd.(300142.SZ)
Profile
Registered Capital:
150.00(RMB MLN)
Employees:
581
Email:
IR@walvax.com.cn

WebSite:
http://www.walvax.com.cn
Tel:
0871-8312779
Fax:
0871-8312779
Introduction from Google Finance
Walvax Biotechnology Co., Ltd. is principally engaged in the research, development, production and distribution of human vaccine products. The Company primarily provides haemophilus influenzae B vaccines, which are applied in the prevention of meningitis, pneumonia, septicemia, cellulitis, arthritis and pharyngitis caused by Hib, as well as group A and group C meningococcal polysaccharide vaccines, which are applied in the prevention of diseases caused by group A and group C meningococcal polysaccharide, such as cerebrospinal meningitis and septicemia. The Company distributes its products primarily in domestic market.
Reports
News      more..
Introduction from Company WebSite

Walvax Biotechnology produces Hib Vaccine (a vaccine for viral hepatitis) and A, C Meningococcal Polysaccharide Conjugate Vaccine, which made up 65.26% and 13.59% of its 2009 revenues, with annual production capacity of eight million and five million vaccines, respectively. The company's clients are mostly disease control centers and medicine dealers. 

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统